Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

Deadline for Registration and Listing of Cosmetic Product

Deadline for Registration and Listing of Cosmetic Product Facilities and Products

Facilities and Products: What Does the Deadline Mean to You, and How is FDA Helping You Comply?

the U.S. Food and Drug Administration (FDA) reminds industry of the resources available to help firms comply with the new registration and listing requirements established by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) by July 1, 2024, consistent with FDA’s Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing.

FDA established a dedicated Registration & Listing of Cosmetic Product Facilities and Products Web page that consolidates links to all resources. 

Reminder: Generally, a cosmetic product listing must include the facility registration number of each facility where the cosmetic product is manufactured or processed.  Thus, it is important for facilities to register before the product listing is completed.

MoCRA provided new authorities to FDA and requirements for industry including:

  • Facility Registration: Cosmetic product manufacturers and processors must register their facilities with FDA, update their registration to reflect changes to their registration information within 60 days of any changes, and renew their registration every two years.
  • Product Listing: A responsible person must list each marketed cosmetic product with FDA, including product ingredients, and provide any updates annually. 

Responsible person means the manufacturer, packer, or distributor of a cosmetic product whose name appears on the label of such cosmetic product in accordance with section 609(a) of the Federal Food, Drug, and Cosmetic Act or section 4(a) of the Fair Packaging and Labeling Act.

Exemptions:

MoCRA exempts certain small businesses from facility registration and product listing requirements.

However, such exemptions do not apply to facilities that manufacture or process, or responsible persons for the following cosmetic products:

  • Products that regularly come into contact with mucus membrane of the eye under customary or usual conditions of use.
  • Products that are injected.
  • Products that are intended for internal use.
  • Products that are intended to alter appearance for more than 24 hours under customary or usual conditions of use and removal by the consumer is not part of such conditions of use. 

Exemptions also exist for certain products and facilities that are subject to requirements for drugs and devices.

In November 2023, FDA issued guidance on its intent to delay enforcement of the requirements for cosmetic product facility registration and cosmetic product listing requirements under MoCRA for six months until July 1, 2024 to help ensure that industry has sufficient time to submit facility registration and product listing information.

In December 2023, FDA issued final guidance on cosmetic product facility registrations and product listings, as mandated by MoCRA. The guidance provides recommendations and instructions to assist persons submitting cosmetic product facility registrations and product listings to FDA.

FDA has made available several options for facility registration and product listing:

  • In October 2023, FDA published a Structured Product Labeling (SPL) Implementation Guide with Validation Procedures, which was updated in December, 2023.  The Implementation Guide can be used to develop SPL authoring tools to transmit SPL-formatted submissions through FDA’s Electronic Submissions Gateway (ESG).
  • In December 2023, FDA also announced the launch of its Cosmetics Direct electronic submission portal, at https://direct.fda.gov/, for registration and listing of cosmetic product facilities and products. We have also developed a user’s guide to Cosmetics Direct, a facility registration tutorial, and a product listing tutorial (See links in Related Resources section below).
  • In January 2024, FDA announced the availability of Xforms, an SPL authoring tool for cosmetic product facility registration and cosmetic product listing.  FDA also announced the availability of Form FDA 5066 and Form FDA 5067 as an additional submission tool for providing cosmetic product facility registration and cosmetic product listing information to FDA. These paper forms are available at Registration & Listing of Cosmetic Product Facilities and Products

For More Information

Related Resources

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.